Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal autologous bone marrow mesenchymal stem cells for chronic diffuse axonal injury
2017-001824-23Phase 2Terminated
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Sep 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in traumatic brain injury (TBI) and Diffuse axonal injury (DAI), sponsored by Fundación de Investigación Biomédica Hospital Puerta de Hierro. Primary endpoints: Clinical efficacy assessed by neurological and functional scales, Neurophysiological efficacy assessments and 1 more. Started Sep 2017; status: terminated.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
traumatic brain injury (TBI)Diffuse axonal injury (DAI)
Beyond the preview
Go deeper on 2017-001824-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001824-23.